{"id":2106,"date":"2019-12-15T17:44:58","date_gmt":"2019-12-15T09:44:58","guid":{"rendered":"https:\/\/credevo.com\/articles\/?p=2106"},"modified":"2025-06-04T13:44:28","modified_gmt":"2025-06-04T05:44:28","slug":"rare-diseases-regulatory-incentives-for-development-of-orphan-drugs-us-europe","status":"publish","type":"post","link":"https:\/\/credevo.com\/articles\/2019\/12\/15\/rare-diseases-regulatory-incentives-for-development-of-orphan-drugs-us-europe\/","title":{"rendered":"Rare Diseases: Regulatory Incentives for Development of Orphan Drugs – The United States & Europe"},"content":{"rendered":"\n

Many regulatory agencies across the world are offering incentives for the development of orphan drugs for rare diseases. These incentives include financial benefits, faster approvals, less stringent clinical data requirements, and many more. The countries that are offering the regulatory incentives for orphan drugs include the US, Europe, Japan, Australia, South Korea, Brazil, and most recently, India.<\/p>\n\n\n\n

\"Rare<\/figure>\n\n\n\n

These incentives have been so supportive and convincingly helpful that they have boosted drug development across the world. <\/p>\n\n\n\n

Orphan drug market<\/h2>\n\n\n\n

Worldwide orphan drug sales are forecast to grow at a CAGR of 12.3% from 2019 to 2024, which is approximately double the rate forecast for the non-orphan drug market. By 2024, orphan drug markets are expected to reach $242bn and capture one-fifth of worldwide prescription sales.<\/p>\n\n\n\n

Orphan drugs and rare diseases<\/h2>\n\n\n\n

An orphan drug<\/h4>\n\n\n\n

An orphan drug<\/strong> is a pharmaceutical agent developed to treat orphan diseases<\/strong> or rare diseases. B<\/strong>ecause they are so rare, and would not be profitable to produce without government assistance. It\u2019s a designation given based on some considerations.<\/p>\n\n\n\n

A rare disease<\/h4>\n\n\n\n

Rare diseases are defined a bit differently across various countries, though the basic consideration remains the same, i.e. the number of patients is very small.<\/p>\n\n\n\n

Let’s first discuss the United States and European regulatory scenarios and benefits. <\/p>\n\n\n\n

Review the next articles in this series for incentives and benefits in other countries for rare disease drug development, rare disease clinical trials, and orphan drug approvals for marketing.<\/em><\/p>\n\n\n\n

Orphan drug regulations in the United States<\/h2>\n\n\n\n

In the United States, a drug or biologic may be designated as an orphan drug if it is to prevent, treat, or diagnose a disease\/condition that occurs in less than 200,000 patients.<\/p>\n\n\n\n

Criteria for orphan designation status in the United States<\/h3>\n\n\n\n

For a drug to get an orphan drug status requires to fulfil the following criteria<\/p>\n\n\n\n